About Ariad Pharmaceuticals
ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: ARIA
- CUSIP: 04033A10
- Previous Close: $23.99
- 50 Day Moving Average: $21.86
- 200 Day Moving Average: $14.14
- 52-Week Range: $4.67 - $23.99
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -57.12
- P/E Growth: 31.31
- Market Cap: $N/A
- Beta: 2.16
- Net Margins: -16.99%
- Return on Assets: -5.12%
Companies Related to Ariad Pharmaceuticals:
- Debt-to-Equity Ratio: -11.28%
- Current Ratio: 3.17%
- Quick Ratio: 3.15%
What is Ariad Pharmaceuticals' stock symbol?
Ariad Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARIA."
Where is Ariad Pharmaceuticals' stock going? Where will Ariad Pharmaceuticals' stock price be in 2017?
10 equities research analysts have issued 12 month target prices for Ariad Pharmaceuticals' stock. Their predictions range from $7.00 to $24.00. On average, they anticipate Ariad Pharmaceuticals' share price to reach $16.54 in the next year.
When will Ariad Pharmaceuticals announce their earnings?
Ariad Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.
Who owns Ariad Pharmaceuticals stock?
Ariad Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (9.33%), BlackRock, Inc (7.70%), Takeda Pharmaceutical Company Limited (6.80%), Sarissa Capital Management LP (6.62%), State Street Corp (4.05%) and Putnam Investments LLC (0.00%). Company insiders that own Ariad Pharmaceuticals stock include Athanese Lavidas, Daniel M Bollag, David L Berstein, Edward M Fitzgerald, Frank Haluska, Hugh M Cole, Maria E Cantor, Martin J Duvall, Massimo Radaelli, Paris Panayiotopoulos and Timothy P Clackson.
Who sold Ariad Pharmaceuticals stock? Who is selling Ariad Pharmaceuticals stock?
Ariad Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Oxford Asset Management, Royce & Associates LP, Opaleye Management Inc., Guggenheim Capital LLC, Commerzbank Aktiengesellschaft FI, National Planning Corp and State Board of Administration of Florida Retirement System. Company insiders that have sold Ariad Pharmaceuticals stock in the last year include Athanese Lavidas, Daniel M Bollag, David L Berstein, Edward M Fitzgerald, Frank Haluska, Hugh M Cole, Maria E Cantor, Martin J Duvall, Massimo Radaelli and Timothy P Clackson.
Who bought Ariad Pharmaceuticals stock? Who is buying Ariad Pharmaceuticals stock?
Ariad Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, FMR LLC, Putnam Investments LLC, Two Sigma Investments LP, A.R.T. Advisors LLC, State Street Corp, Advisory Research Inc. and Palo Alto Investors LLC.
How do I buy Ariad Pharmaceuticals stock?
Shares of Ariad Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Ariad Pharmaceuticals stock cost?
One share of Ariad Pharmaceuticals stock can currently be purchased for approximately $23.99.